Abstract： Objective:To investigate and analyze the clinical efficacies of different courses of intratympanic methylprednisolone perfusion combined with hyperbaric oxygen（HBO）therapy in sudden deafness patients with total hearing loss.Methods:We selected 114 sudden deafness patients with total hearing loss who were hospitalized in the department of otorhinolaryngology of Zhengzhou People's Hospital from March 2020 to March 2022. The patients were divided equally into group A，B，and C using the digital random table method，with 38 patients in each group. All the patients were treated according to their own courses，with intratympanic methylprednisolone perfusion being given 3，5，or 7 times，respectively，for group A，B，or C，and HBO therapy for 10，15，20 times，respectively. During treatment，if the patient’s hearing was evaluated as full recovery for three times consecutively，the HBO therapy would therefor be stopped. Pure tone audiometry（PTA）was reviewed before and after the treatment course，according to the Guidelines for Diagnosis and Treatment of Sudden Deafness（2015）. Results:The total effective rates were 63.16%，65.79%，and 71.05% for group A，B，and C，respectively，with no statistically significant difference（ P>0.05）. After treatment，the PTAs for all three groups were decreased，with statistically significant differences（ P<0.05）. Conclusion:The combination of intratympanic methylprednisolone perfusion with HBO therapy can significantly improve hearing in sudden deafness patients with total hearing loss despite the courses，but there was no statistically significant difference of the clinical efficacy among the three groups. It is recommended that the combination therapy be performed as early as possible in these patients. The adverse reactions and complications during treatment should be closely monitored at the same time.